suvemcitug
Term · Oncology and biomedicine · MLC-T-ONC-016932
A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.
| Identifier | MLC-T-ONC-016932 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | sevacizumab |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016932",
"term": "suvemcitug",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.",
"synonyms": [
"sevacizumab"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/suvemcitug/"
}
Record 15,850 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.